Evidence map›Paper›PMID 41350967›Full record

ReviewPharmaceutical research2026

Biotechnology in Brazil: Current State, Gaps, and Strategic Recommendations.

Frederico Severino Martins, Gabriel Bottos, Amanda Silva Hecktheuer, Leonardo Luiz Borges

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Frederico Severino MartinsInstitute of Technology and Research (ITP), Av. Murilo Dantas, 300, Aracaju, Sergipe, 49010-390, Brazil. fredseverinomartins@gmail.com.ORCID http://orcid.org/0000-0001-5555-8771
Gabriel BottosVesper Biotechnologies, Rod. José Carlos Daux, 6997, Florianópolis, SC, 88050-000, Brazil.
Amanda Silva HecktheuerVesper Biotechnologies, Rod. José Carlos Daux, 6997, Florianópolis, SC, 88050-000, Brazil.
Leonardo Luiz BorgesLaboratory for Research, Development & Innovation of Biodiversity Products, State University of Goiás, Anápolis, GO, 75132-903, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biotechnology is becoming a key driver of innovation in health, agriculture, industry, and sustainability worldwide. Brazil has made significant progress in this field, thanks to its strong research institutions, diverse ecosystems, and active pharmaceutical and agribusiness sectors. However, despite these strengths, the country still faces critical barriers that limit its global competitiveness in biotechnology. These include a lack of coordination between academia and industry, limited early-stage investment, underdeveloped infrastructure, regulatory delays, and low levels of internationalization. This article provides a comprehensive overview of the biotechnology landscape in Brazil. It analyzes the global context, highlights the country's current position, and identifies gaps and opportunities across the biopharmaceutical value chain. Drawing from international benchmarks and national data, the paper proposes five strategic directions to strengthen Brazil's biotechnology ecosystem: (1) fostering translational science and innovation; (2) expanding access to capital and reducing investment risk; (3) improving infrastructure through shared platforms; (4) modernizing regulatory frameworks; and (5) positioning Brazil in global markets through its unique strengths, such as biodiversity, public health expertise, and agricultural leadership. The article concludes that Brazil has the scientific foundation and market potential to become a global player in biotechnology. However, realizing this potential will require coordinated efforts from government, industry, and academia. With the right policies and investments, Brazil can turn scientific advances into innovative solutions that benefit both its population and the global bioeconomy.

Indexed as

BiotechnologyAgricultureBrazilDrug IndustryHumansTranslational Research, Biomedicalhealth industrypharmaceutical innovationpharmacoeconomics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.